{
    "nctId": "NCT00821964",
    "briefTitle": "Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer",
    "officialTitle": "Phase II Study of Topical Imiquimod and Weekly Abraxane for the Treatment of Breast Cancer Cutaneous Metastases",
    "overallStatus": "COMPLETED",
    "conditions": "Male Breast Cancer, Recurrent Breast Cancer, Skin Metastases, Stage IV Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 15,
    "primaryOutcomeMeasure": "Anti-tumor Effects of Imiquimod as Assessed by Modified World Health Organization (WHO) Criteria",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with advanced stage refractory breast cancer\n* Progressive or relapsed disease following standard therapy with chemotherapy and/or surgery, and/or radiation\n* Patients must have measurable (bi-dimensional) chest wall disease and/or cutaneous metastatic lesions\n* Patients must be at least 7 days from last chemotherapy and 30 days from local radiotherapy and/or systemic steroids\n* Patients on bisphosphonates, trastuzumab, lapatinib and/or hormonal therapy are eligible\n* White blood cell count \\>= 1000/ul\n* Absolute neutrophil count (ANC) \\>= 1200/ul\n* Platelets \\> 75,000/ul\n* Serum creatinine =\\< 2.0 mg/dL, a creatinine clearance \\> 60 ml/min\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\< 2 X upper limit normal (ULN)\n* Total bilirubin \\< 2 X ULN\n* Patients must have a Performance Status Score (Eastern Cooperative Oncology Group \\[ECOG\\] Scale) =\\< 2\n* Patients must have recovered from major infections and/or surgical procedures and, in the opinion of the investigator, not have a significant active concurrent medical illness precluding protocol treatment\n* Men and women of reproductive ability must agree to contraceptive use during the study and for 1 month after imiquimod/Abraxane treatment is discontinued\n\nExclusion Criteria:\n\n* Patients with prior allergic reaction to taxanes\n* Patients with any clinically significant active autoimmune disease requiring active treatment with systemic steroids or other immunomodulators\n* Pregnant or breast-feeding women\n* Patients with peripheral neuropathy \\>= Grade 2",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}